Clinical trial

Pediatric Pectointercostal and ESP Block in Cardiac Surgery Surgery

Name
Pediatric Pectointercostal
Description
American Society of Anaesthesiologist physical status II-III, aged between 2, 12 patients which underwent open cardiac surgery will recruited to this study. These subjects will Ultrasound (USG) guided erector spinae block will perform at T6 level (bilaterally) and pectointercostal plane block at 4-5 intercostal space to the all patient under general anaesthesia. Totally bupivacaine %0.25 2.5 mg/kg will use blocks. 2 ml %0.25 bupivacain will apply to the chest tube area at the end of surgery. 0.1 microgram/kg morphine will apply intravenously at last 30 minutes of surgery postoperative analgesia to all patients. Postoperative pain and agitation assessment will perform with FLACC and Watcha scores
Trial arms
Trial start
2022-10-15
Estimated PCD
2023-08-15
Trial end
2023-08-15
Status
Recruiting
Phase
Early phase I
Treatment
Pectointercostal and ESP block
Both Pectointercostal at between 4th and 5th costa and ESP block will apply at thoracal 6 level to the patient.
Arms:
No Block, Pectointercostal and ESP block
Other names:
Fascia plane blocks
Size
60
Primary endpoint
Postoperative analgesia
24 hours in Postanesthesia care unit (PACU)
Postoperative morphine consumption
24 hours in Postanesthesia care unit (PACU)
Eligibility criteria
Inclusion Criteria: * Ages between 2-12 years * ASA II-III children * The children who undergoing open heart surgery Exclusion Criteria: * Coagulopaty * Allergy of local anesthetic * Liver and renal failure * Obesity (BMI \>35kg/m2) * Infection at the block area
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}
Updated at
2023-04-27

1 organization

1 product

1 indication